

Press Release

13 December 2018

Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.

Immunicum AB (publ) ("Immunicum" or the "Company") announced today that the share issue with preferential rights for existing shareholders has been completed and that 5,950,924 shares, corresponding to 29 percent of the share issue, were subscribed for by the use of subscription rights. Furthermore, 197,015 shares, corresponding to 1 percent of the share issue, were subscribed for without the use of subscription rights. The remaining part of the Rights Issue, corresponding to 14,235,473 shares or 70 percent of the share issue, was subscribed for by guarantors. Of the total capital raise of SEK 351M, 34 percent corresponding to SEK 121M, was subscribed for by guarantors.

Allotment of shares has been made in accordance with the principles set out in the prospectus that was published by the Company on November 23, 2018. Notice of allotment of shares subscribed for without the use of subscription rights is expected to be distributed on December 14, 2018. Subscribed and allotted shares shall be paid for in cash by the settlement date on December 19, 2018, in accordance with instructions on the contract note. Nominee shareholders will receive notice of allotment in accordance with each nominee's internal routines.

In parallel with the Rights Issue and as previously announced, Immunicum is implementing a directed issue of a total of SEK 178M, mainly to a number of institutional investors including the Fourth AP Fund, Gladiator, Second AP Fund, Alfred Berg, Nordic Cross and Adrigo, as well as to a number of private investors. The directed issue is conducted at the same subscription price as in the Rights Issue.

Immunicum raised SEK 351M before issue costs through the share issues and the Company's share capital increase from SEK 2,547,926.55 to SEK 4,612,876.55. The number of shares will increase from 50,958,531 shares to 92,257,531 shares when the share issues have been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). Registration is expected in week three of 2019. Conversion of paid subscribed shares (BTA) to shares is expected in week four of 2019.

"We have now achieved a pivotal step for the Company by securing a strong group of institutional investors and a solid financial position. This allows for continued investments in our clinical development programs to reach several important value inflection points over the next three years. Already in 2019, we expect topline results from the Phase II MERECA renal cancer trial, Phase I/II results in GIST as well as safety and potential early efficacy data from the multi-indication Phase Ib/II ILIAD study. We will continue to move forward with our preclinical studies and the development of a solid commercial manufacturing process to shorten time to market," said Carlos de Sousa, CEO of Immunicum.

Financial, strategic and legal advisor

Erik Penser Bank is the financial advisor and Asperia AB is the strategic advisor to Immunicum in connection with the Share Issues. Furthermore, Advokatfirman Delphi is the legal advisor to the Company in connection with the Share Issues.

The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 13 December 2018 at 6.00 pm CET.

FOR MORE INFORMATION, PLEASE CONTACT:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com

MEDIA RELATIONS

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

ABOUT IMMUNICUM AB (PUBL)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
